ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Inventory for the quarter ending September 30, 2024: USD 0.00

ZyVersa Therapeutics, Inc. Inventory is USD 0.00 for the quarter ending September 30, 2024, a 0.00% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

ZyVersa Therapeutics, Inc. Inventory for the quarter ending September 30, 2023 was USD 0.00.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years